This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Cardiovascular safety of testosterone replacement therapy in men

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Cardiovascular Safety of Testosterone-Replacement Therapy

  • RCT (n=5246 men aged 45-80 years with hypogonadism & pre-existing/high risk of CVD (cardiovascular disease)) (1)
    • mean (+/-SD) duration of treatment was 21.7+/-14.1 months, and the mean follow-up was 33.0+/-12.1 months
    • found transdermal testosterone-replacement therapy to be noninferior to placebo for incidence of major adverse cardiac events (7.0% vs 7.3%; HR 0.96; 95% 0.78 to 1.17; P<0.001 for noninferiority)

A previous review stated (2):

  • in men, testosterone levels begin to decrease after age 40, and this decrease has been associated with an increase in all-cause mortality and cardiovascular (CV) risk
  • low testosterone levels in men may increase their risk of developing coronary artery disease (CAD), metabolic syndrome, and type 2 diabetes
  • reduced testosterone levels in men with congestive heart failure (CHF) is associated with a poor prognosis and is associated with increased mortality
  • testosterone replacement therapy (TRT) has been shown to improve myocardial ischemia in men with CAD, improve exercise capacity in patients with CHF, and improve serum glucose levels, HbA1c, and insulin resistance in men with diabetes and prediabetes.

Reference:

  • Lincoff AM et al. Cardiovascular Safety of Testosterone-Replacement Therapy. NEJM (June 16th 2023)
  • Goodale T, Sadhu A, Petak S, Robbins R. Testosterone and the Heart. Methodist Debakey Cardiovasc J. 2017 Apr-Jun;13(2):68-72. doi: 10.14797/mdcj-13-2-68. PMID: 28740585; PMCID: PMC5512682.

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.